{"id":100126419,"date":"2025-04-02T16:41:15","date_gmt":"2025-04-02T13:41:15","guid":{"rendered":"https:\/\/europeanhealtheconomics.com\/?p=100126419"},"modified":"2026-01-01T12:54:19","modified_gmt":"2026-01-01T10:54:19","slug":"market-access-in-finland","status":"publish","type":"post","link":"https:\/\/europeanhealtheconomics.com\/fr\/blog\/market-access-in-finland\/","title":{"rendered":"Understanding Market Access in Finland"},"content":{"rendered":"

A Practical Guide for Market Access Managers.<\/h2>\n\n\n\n

Bringing a new medicine to the Finnish market? Are you confident your product is classified correctly? Have you chosen the right comparator? Do your health economic models reflect local inputs, and will your evidence satisfy both national and regional authorities in Finland? For many market access managers, these are the questions that come up early, and if left unanswered, they can lead to delays, extra work, or even a negative reimbursement decision. Add in overlapping submissions and limited team capacity, and the process can quickly become overwhelming, especially if you or your team have little or no prior experience with the market access process in Finland.<\/p>\n\n\n\n

This guide is for market access and HEOR managers like you, those juggling multiple projects, tight timelines, diverse stakeholders, and internal expectations. It gives you a clear overview of the Finnish system, along with practical guidance on how involving a local freelance expert at the right time can support your submission.<\/p>\n\n\n\n

At EuropeanHealthEconomics.com, our local freelance experts in market access and health economics help managers navigate the reimbursement process in Finland, avoid costly mistakes, and secure both national and regional approvals. We also ease the workload and reduce the pressure on you and your team. Get in touch to explore how we can support your next submission<\/a>.<\/p>\n\n\n\n

The Outpatient vs. Hospital Medicine Divide in Finland<\/h2>\n\n\n\n
\"Close-up<\/figure>\n\n\n\n

A key feature of Finland\u2019s market access system lies a key distinction: outpatient versus hospital medicines. Although the HTA content requirements for both medicine types are broadly the same; covering therapeutic value, PICO framework, and economic evaluation, the processes are entirely separate.<\/p>\n\n\n\n

Outpatient Therapies<\/h3>\n\n\n\n

Outpatient therapies<\/strong> are typically oral or self-administered treatments, like tablets or subcutaneous injections, dispensed through pharmacies and used by patients themselves. What matters most for classification is not where the medicine is prescribed, but how it is administered<\/strong>. Even therapies prescribed by specialists, such as oral oncology treatments, are often considered outpatient and assessed as such. These medicines require a separate reimbursement decision from the Pharmaceuticals Pricing Board (PPB) before market access is granted.<\/p>\n\n\n\n

The HTA and reimbursement process for outpatient products is managed centrally by the PPB. It follows defined steps with clear expectations and relatively predictable timelines. However, for high-cost medicines, the process often includes confidential pricing negotiations<\/strong>, which require careful evidence planning and internal alignment prior to submission.<\/p>\n\n\n\n

Hospital Medicines<\/h3>\n\n\n\n

Hospital medicines<\/strong> are given in healthcare settings and typically include intravenous treatments or subcutaneous products that require clinical supervision to ensure safe and proper use. Unlike outpatient medicines, these follow a more fragmented access route, involving several public sector bodies and multiple layers of decision-making.<\/p>\n\n\n\n

The process starts with the Finnish Medicines Agency<\/strong> (Fimea), which carries out the Health Technology Assessment (HTA), looking at both the clinical value and the economic case. Fimea then forwards its evaluation to the Council for Choices in Health Care in Finland<\/strong> (COHERE Finland), which provides a national recommendation on whether the treatment should be introduced. From there, confidential pricing discussions may take place, but the final decision to adopt the medicine lies with each of the 21 regional Wellbeing Services Counties<\/strong>, each with its own priorities, timelines, and budget constraints.<\/p>\n\n\n\n

In practise, getting a hospital medicine approved in Finland means working through several layers of decision-making, each with its own timelines, priorities, and budget constraints. For companies unfamiliar with the system, or without a local affiliate, it can quickly become overwhelming. The process is rarely linear, and small missteps early on can turn into major delays later.<\/p>\n\n\n\n

Freelance Support for Market Access in Finland<\/h3>\n\n\n\n

That\u2019s why many market access managers bring in a Finnish freelance consultant<\/strong> early in the process. Someone who knows the system, understands how decisions are made, and can guide you through the right steps from the start. An experienced local expert<\/strong> can help classify the product correctly, shape your evidence to match expectations, and align your dossier with the right stakeholders, avoiding confusion and unnecessary rework. If your team is already stretched across multiple submissions, this early clarity can save time, reduce stress, and keep your launch plans on track.<\/p>\n\n\n\n

Comparison: Outpatient vs. Hospital Medicine Access in Finland<\/h5>\n\n\n\n
Aspect<\/th>Outpatient Medicines<\/th>Hospital Medicines<\/th><\/tr><\/thead>
Decision Authority<\/strong><\/td>PPB (national)<\/td>Fimea \u2192 COHERE \u2192 Regional Counties<\/td><\/tr>
Key Requirement<\/strong><\/td>Cost-effectiveness vs. appropriate comparator<\/td>Alignment with local healthcare priorities and budgets<\/td><\/tr>
Timeline<\/strong><\/td>6\u201312 months<\/td>9\u201318 months (varies by county)<\/td><\/tr>
Critical Challenge<\/strong><\/td>Navigating confidential pricing expectations<\/td>Coordinating stakeholder buy-in across 21 separate regions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

HTA Submissions in Finland<\/h2>\n\n\n\n

Navigating National and Regional Requirements<\/h3>\n\n\n\n

While Finland\u2019s HTA requirements align with the EU HTA Regulation, the national process differs in several important ways. For outpatient medicines, the PPB expects rigorous economic models using Finnish-specific data <\/strong>et comparators<\/strong>, even if those comparators are not reimbursed locally. For hospital therapies, the submission is only part of the work. Once Fimea and COHERE have given their views, the real challenge lies in securing regional approvals<\/strong>. This is where many internal teams get stretched thin. Adapting global models to Finnish needs is already time-consuming; layering in regional strategy and stakeholder engagement can overwhelm even experienced teams.<\/p>\n\n\n\n

Why Language and Local Expertise Are Critical<\/h2>\n\n\n\n

The language barrier<\/strong> is another practical challenge. Many key documents, guidelines, and health system information are only available in Finnish, and interactions with KOLs, or decision-makers in Wellbeing Services Counties often happen in Finnish too. A local freelance expert can help you to bridge these gaps.

While submissions in English are accepted by PPB, Fimea, and regional procurement authorities, submissions in Finnish<\/strong> are often preferred, particularly because the language skills of subject matter reviewers can vary. Additionally, decisions are typically issued in Finnish or Swedish, the official languages of Finland<\/p>\n\n\n\n

How Our Finnish Freelance Experts Help You Deliver Results<\/h3>\n\n\n\n

Many market access managers think of freelance support only when timelines are at risk. But involving a local consultant early often leads to smoother submissions and less firefighting later. At EuropeanHealthEconomics.com, we connect you with Finnish freelance market access experts <\/strong>who have already handled similar submissions in Finland, whether it\u2019s a new outpatient launch or a regionally complex hospital therapy.<\/p>\n\n\n\n

Finland is also showing increasing interest in outcomes-based pricing<\/strong>, particularly for innovative or high-cost therapies. But these agreements must comply with Finnish procurement law, which limits what kinds of terms are possible. A local freelance expert can help you understand what has been done before, what authorities are open to, and how to structure proposals in a way that meets both expectations and legal requirements.<\/p>\n\n\n\n

Your Roadmap to Market Access Success in Finland<\/h2>\n\n\n\n
\"Map<\/figure>\n\n\n\n

For managers balancing multiple submissions, tight timelines, and limited internal capacity, working with the right freelance expert can mean the difference between staying on track and missing key launch milestones. <\/p>\n\n\n\n

Based on our experience, here\u2019s what tends to work best:<\/p>\n\n\n\n

    \n
  1. Classify your product early and accurately<\/strong>, borderline cases can lead to delays if misjudged. Speak with someone who\u2019s handled both outpatient and hospital submissions before.<\/li>\n\n\n\n
  2. Involve a freelancer during the strategy phase<\/strong>, not just at submission. This helps identify data gaps early and avoids unnecessary rework. <\/li>\n\n\n\n
  3. Tailor your messaging to regional realities<\/strong>. County-level differences in disease burden, budgets, and political context can all influence adoption, even after approval. <\/li>\n\n\n\n
  4. Do not underestimate the importance of fluent Finnish documentation<\/strong>. It\u2019s not just about translation, it\u2019s about clarity, consistency, and getting it right the first time.<\/li>\n<\/ol>\n\n\n\n

    How Our Finnish Freelance Experts Help You Deliver Results<\/h2>\n\n\n\n

    A Finnish freelance expert can support your market access project in several ways. They can lead your PPB submission <\/strong>from start to finish, adapt global HTA<\/strong> content to meet Finnish expectations, and prepare cost-effectiveness models and pricing documentation aligned with national requirements. If you’re working on a hospital product, they can support your Fimea and COHERE submissions, ensure technical translations into Finnish are accurate, and help you engage with<\/strong> the right regional stakeholders<\/strong>. For high-cost medicines, they can also contribute to confidential pricing materials and help your team prepare for managed entry discussions. Whether you need someone to take the lead or step in as specialist support, we\u2019ll connect you with the right freelancer for your submission.<\/p>\n\n\n\n

    Accelerate Your Market Access Journey Today<\/h3>\n\n\n\n

    Delays are costly, and often avoidable. At EuropeanHealthEconomics.com, we connect you with freelance experts who specialise in Finnish market access. They understand the local process and can work alongside your team without slowing things down. Whether you\u2019re preparing your first PPB submission or trying to speed up county-level adoption, a Finnish freelance expert can bring the local experience your project needs.<\/p>\n\n\n\n